23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Fate Therapeutics, Inc. › 2025-2026

Fate Therapeutics, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Fate Therapeutics, Inc.’s Form 8-K, filed June 15, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 6Ballot items
  • 140Asset managers, any item
  • 905Fund votes
  • June 12, 2026Meeting date

Results at a glance

Meeting of June 12, 2026: 6 items on Fate Therapeutics, Inc.’s Form 8-K, filed June 15, 2026: 3 elected · 3 passed (calculated).

Dissent

Notable dissent: 1 other board item (23.5% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Fate Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Fate Therapeutics, Inc.

These tallies are Fate Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 15, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Fate Therapeutics, Inc. — official shareholder meeting results, meeting held June 12, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Robert S. Epstein, M.D., M.S. 59,332,820---- 1,717,84226,083,760 97%Elected—
Elect Director: Karin Jooss, Ph.D. 59,655,584---- 1,395,07826,083,760 98%Elected—
Elect Director: Laura J. Hamill 60,850,004---- 200,65826,083,760 99.7%Elected—
(ii) Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. 86,552,927308,582272,913 --0 99.6%Passed (calculated)—
(iii) Non-binding advisory vote on the compensation of the Company's named executive officers. 59,168,6891,808,66973,304 --26,083,760 97%Passed (calculated)—
(iv) Approval of an amendment and restatement of the 2022 A&R Plan to increase the number of shares of Common Stock reserved for issuance thereunder. 46,645,60714,304,810100,245 --26,083,760 77%Passed (calculated)—

Source: Fate Therapeutics, Inc., Form 8-K, filed with the SEC on June 15, 2026 — read the filing on EDGAR.

How asset managers voted at the Fate Therapeutics, Inc. 2025-2026 meeting

140 asset managers disclosed a vote on at least one Fate Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Karin Jooss, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 59,655,584WITHHELD: 1,395,078
Details: description as filed, official tally, votes by 43 asset managers

Description as filed by funds: Election of Class I Directors: Karin Jooss, Ph.D.

Fate Therapeutics, Inc.’s own tally for this item (“Elect Director: Karin Jooss, Ph.D.”): 59,655,584 for, 1,395,078 withheld, per its Form 8-K filed June 15, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All matters submitted to a vote of the Company's stockholders at the Annual Meeting were approved and all director nominees were elected.”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 43 asset managers below reported 18,800,389 for, 119,786 withheld, 5 abstained.

FOR
FOR: 18,800,389ABSTAIN: 5WITHHOLD: 119,786
Largest asset managers voting on “Election of Class I Directors: Karin Jooss, Ph.D.” at Fate Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard8,334,8350 59,707For
BlackRock4,292,2010 00For
Fidelity2,222,0490 00For
BRUCE FUND INC789,1880 00For
Charles Schwab756,9760 00For
Invesco347,4690 00For
Equitable190,3280 0109,540Mixed
TIAA271,4830 00For
Dimensional255,8440 00For
AQR194,9780 00For
BRIDGEWAY FUNDS INC185,0000 00For
QUANTITATIVE MASTER SERIES LLC177,4790 00For
Goldman Sachs166,6540 00For
Lincoln Financial78,0440 00For
Northern Trust61,8620 00For
MASTER INVESTMENT PORTFOLIO58,2630 00For
Global X51,0840 00For
Bridge Builder Trust45,9520 00For
Pacific Life43,8510 00For
Nationwide35,6800 00For
Thrivent33,1530 00For
Blackstone Alternative Investment Funds25,5000 00For
Voya22,5020 00For
SEI18,6000 00For
ProShares16,1440 00For

Showing the 25 largest of 43 asset managers. All 43 are in the interactive database (link above).

Elect Director: Laura J. Hamill

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%
FOR: 60,850,004WITHHELD: 200,658
Details: description as filed, official tally, votes by 43 asset managers

Description as filed by funds: Election of Class I Directors: Laura J. Hamill

Fate Therapeutics, Inc.’s own tally for this item (“Elect Director: Laura J. Hamill”): 60,850,004 for, 200,658 withheld, per its Form 8-K filed June 15, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All matters submitted to a vote of the Company's stockholders at the Annual Meeting were approved and all director nominees were elected.”
Support: 99.7% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 43 asset managers below reported 18,920,180 for.

FOR
FOR: 18,920,180
Largest asset managers voting on “Election of Class I Directors: Laura J. Hamill” at Fate Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard8,344,5470 00For
BlackRock4,292,2010 00For
Fidelity2,222,0490 00For
BRUCE FUND INC789,1880 00For
Charles Schwab756,9760 00For
Invesco347,4690 00For
Equitable299,8680 00For
TIAA271,4830 00For
Dimensional255,8440 00For
AQR194,9780 00For
BRIDGEWAY FUNDS INC185,0000 00For
QUANTITATIVE MASTER SERIES LLC177,4790 00For
Goldman Sachs166,6540 00For
Lincoln Financial78,0440 00For
Northern Trust61,8620 00For
MASTER INVESTMENT PORTFOLIO58,2630 00For
Global X51,0840 00For
Bridge Builder Trust45,9520 00For
Pacific Life43,8510 00For
Nationwide35,6800 00For
Thrivent33,1530 00For
Blackstone Alternative Investment Funds25,5000 00For
Voya22,5020 00For
SEI18,6000 00For
ProShares16,1440 00For

Showing the 25 largest of 43 asset managers. All 43 are in the interactive database (link above).

Elect Director: Robert S. Epstein, M.D., M.S.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 59,332,820WITHHELD: 1,717,842
Details: description as filed, official tally, votes by 43 asset managers

Description as filed by funds: Election of Class I Directors: Robert S. Epstein, M.D., M.S.

Fate Therapeutics, Inc.’s own tally for this item (“Elect Director: Robert S. Epstein, M.D., M.S.”): 59,332,820 for, 1,717,842 withheld, per its Form 8-K filed June 15, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All matters submitted to a vote of the Company's stockholders at the Annual Meeting were approved and all director nominees were elected.”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 43 asset managers below reported 18,558,811 for, 361,365 withheld, 4 abstained.

FOR
FOR: 18,558,811ABSTAIN: 4WITHHOLD: 361,365
Largest asset managers voting on “Election of Class I Directors: Robert S. Epstein, M.D., M.S.” at Fate Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard8,330,1310 414,412For
BlackRock4,292,2010 00For
Fidelity2,222,0490 00For
BRUCE FUND INC789,1880 00For
Charles Schwab756,9760 00For
Invesco347,4690 00For
Equitable190,3280 0109,540Mixed
TIAA271,4830 00For
Dimensional255,8440 00For
AQR194,9780 00For
BRIDGEWAY FUNDS INC185,0000 00For
QUANTITATIVE MASTER SERIES LLC177,4790 00For
Goldman Sachs00 0166,654Withhold
Lincoln Financial78,0440 00For
Northern Trust00 061,862Withhold
MASTER INVESTMENT PORTFOLIO58,2630 00For
Global X51,0840 00For
Bridge Builder Trust45,9520 00For
Pacific Life43,8510 00For
Nationwide35,6800 00For
Thrivent33,1530 00For
Blackstone Alternative Investment Funds25,5000 00For
Voya22,5020 00For
SEI18,6000 00For
ProShares16,1440 00For

Showing the 25 largest of 43 asset managers. All 43 are in the interactive database (link above).

(iv) Approval of an amendment and restatement of the 2022 A&R Plan to increase the number of shares of Common Stock…

Calculated outcomeCOMPENSATIONPassed (calculated)

77% Majority: yes · of votes cast

FOR 77%AGAINST
FOR: 46,645,607AGAINST: 14,304,810
Details: description as filed, official tally, votes by 43 asset managers

Description as filed by funds: TO APPROVE A PROPOSAL TO AMEND AND RESTATE THE COMPANY'S 2022 STOCK OPTION AND INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK RESERVED FOR ISSUANCE THEREUNDER.

Fate Therapeutics, Inc.’s own tally for this item (“(iv) Approval of an amendment and restatement of the 2022 A&R Plan to increase the number of shares of Common Stock reserved for issuance thereunder.”): 46,645,607 for, 14,304,810 against, per its Form 8-K filed June 15, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 77% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 43 asset managers below reported 17,025,443 for, 1,894,736 against.

FOR
FOR: 17,025,443AGAINST: 1,894,736
Largest asset managers voting on “TO APPROVE A PROPOSAL TO AMEND AND RESTATE THE COMPANY'S 2022 STOCK OPTION AND INCENTIVE PLAN TO INCREASE THE ” at Fate Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard8,334,7849,762 00For
BlackRock4,292,2010 00For
Fidelity2,222,0490 00For
BRUCE FUND INC789,1880 00For
Charles Schwab756,9760 00For
Invesco0347,469 00Against
Equitable190,328109,540 00Mixed
TIAA0271,483 00Against
Dimensional0255,844 00Against
AQR0194,978 00Against
BRIDGEWAY FUNDS INC0185,000 00Against
QUANTITATIVE MASTER SERIES LLC177,4790 00For
Goldman Sachs0166,654 00Against
Lincoln Financial078,044 00Against
Northern Trust061,862 00Against
MASTER INVESTMENT PORTFOLIO58,2630 00For
Global X51,0840 00For
Bridge Builder Trust45,9520 00For
Pacific Life43,8510 00For
Nationwide35,6800 00For
Thrivent033,153 00Against
Blackstone Alternative Investment Funds025,500 00Against
Voya022,502 00Against
SEI18,6000 00For
ProShares016,144 00Against

Showing the 25 largest of 43 asset managers. All 43 are in the interactive database (link above).

(iii) Non-binding advisory vote on the compensation of the Company's named executive officers.

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 9 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 59,168,689AGAINST: 1,808,669

Prior year: 92.4% for (May 29, 2025 meeting) ▲ 4.7 pts

Details: description as filed, official tally, votes by 140 asset managers

Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement.

Fate Therapeutics, Inc.’s own tally for this item (“(iii) Non-binding advisory vote on the compensation of the Company's named executive officers.”): 59,168,689 for, 1,808,669 against, per its Form 8-K filed June 15, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 43 asset managers voting on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as dis” at Fate Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard8,344,5415 00For
BlackRock4,292,2010 00For
Fidelity2,222,0490 00For
BRUCE FUND INC789,1880 00For
Charles Schwab756,9760 00For
Invesco347,4690 00For
Equitable299,8680 00For
TIAA271,4830 00For
Dimensional255,8440 00For
AQR194,9780 00For
BRIDGEWAY FUNDS INC0185,000 00Against
QUANTITATIVE MASTER SERIES LLC177,4790 00For
Goldman Sachs166,6540 00For
Lincoln Financial78,0440 00For
Northern Trust061,862 00Against
MASTER INVESTMENT PORTFOLIO58,2630 00For
Global X51,0840 00For
Bridge Builder Trust45,9520 00For
Pacific Life43,8510 00For
Nationwide35,6800 00For
Thrivent33,1530 00For
Blackstone Alternative Investment Funds25,5000 00For
Voya22,5020 00For
SEI18,6000 00For
ProShares16,1440 00For

Fund voting reports, all 43 managers: 18,673,312 for, 246,867 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 112 asset managers voting on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as dis” at Fate Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Redmile Group, LLC12,872,9460 00For
BlackRock4,091,262194 00For
ACADIAN ASSET MANAGEMENT LLC3,029,74751,458 00For
GEODE CAPITAL MANAGEMENT, LLC2,590,4290 00For
AQR1,699,4260 00For
State Street1,476,3295,160 00For
Two Sigma992,6880 00For
Irenic Capital Management LP878,0530 00For
Invesco802,4460 00For
Charles Schwab757,3830 00For
Vanguard724,3060 00For
DAFNA Capital Management LLC550,0000 00For
Renaissance518,7880 00For
Connor, Clark & Lunn Investment Management Ltd.471,9580 00For
Northern Trust4,108403,931 00Against
MELLON INVESTMENTS Corp374,3290 00For
Nuveen339,0730 00For
Citadel324,9430 00For
Man Group plc303,5870 00For
AllianceBernstein187,7600 00For
BRIDGEWAY CAPITAL MANAGEMENT, LLC0185,000 00Against
T. Rowe Price132,9980 00For
Goldman Sachs127,9970 00For
National Philanthropic Trust00 00Not Voted
Dimensional90,6980 00For

Institutional-manager reports, all 112 managers: 34,287,068 for, 772,933 against, 4,500 abstained, 128,000 not voted. Showing the 25 largest; every one is in the interactive database (link above).

(ii) Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

99.6% Majority: yes · of votes cast

FOR 99.6%
FOR: 86,552,927AGAINST: 308,582

Prior year: 99.3% for (May 29, 2025 meeting) ▲ 0.3 pts

Details: description as filed, official tally, votes by 43 asset managers

Description as filed by funds: TO APPROVE THE RATIFICATION OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2026.

Fate Therapeutics, Inc.’s own tally for this item (“(ii) Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”): 86,552,927 for, 308,582 against, per its Form 8-K filed June 15, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 43 asset managers below reported 18,920,180 for.

FOR
FOR: 18,920,180
Largest asset managers voting on “TO APPROVE THE RATIFICATION OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE C” at Fate Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard8,344,5470 00For
BlackRock4,292,2010 00For
Fidelity2,222,0490 00For
BRUCE FUND INC789,1880 00For
Charles Schwab756,9760 00For
Invesco347,4690 00For
Equitable299,8680 00For
TIAA271,4830 00For
Dimensional255,8440 00For
AQR194,9780 00For
BRIDGEWAY FUNDS INC185,0000 00For
QUANTITATIVE MASTER SERIES LLC177,4790 00For
Goldman Sachs166,6540 00For
Lincoln Financial78,0440 00For
Northern Trust61,8620 00For
MASTER INVESTMENT PORTFOLIO58,2630 00For
Global X51,0840 00For
Bridge Builder Trust45,9520 00For
Pacific Life43,8510 00For
Nationwide35,6800 00For
Thrivent33,1530 00For
Blackstone Alternative Investment Funds25,5000 00For
Voya22,5020 00For
SEI18,6000 00For
ProShares16,1440 00For

Showing the 25 largest of 43 asset managers. All 43 are in the interactive database (link above).

Largest Fate Therapeutics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 116,272,513 shares outstanding at the time of that meeting.

Fund voting reports: top Fate Therapeutics, Inc. shareholders by shares voted on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive…”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 7.18%
2BlackRock 3.69%
3Fidelity 1.91%
4BRUCE FUND INC 0.68%
5Charles Schwab 0.65%
6Invesco 0.30%
7Equitable 0.26%
8TIAA 0.23%
9Dimensional 0.22%
10AQR 0.17%
Institutional-manager reports: top Fate Therapeutics, Inc. shareholders by shares voted on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive…”, 2025-2026
#Asset manager % of shares outstanding
1Redmile Group, LLC 11.07%
2BlackRock 3.52%
3ACADIAN ASSET MANAGEMENT LLC 2.65%
4GEODE CAPITAL MANAGEMENT, LLC 2.23%
5AQR 1.46%
6State Street 1.27%
7Two Sigma 0.85%
8Irenic Capital Management LP 0.76%
9Invesco 0.69%
10Charles Schwab 0.65%

Reported Fate Therapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Fate Therapeutics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Redmile Group, LLC18,229,078 15.68%Schedule 13D, filed April 22, 2026
Entities affiliated with Redmile Group, LLC12,872,946 11.07%Proxy statement (DEF 14A), table as of March 31, 2026
ARK Investment Management LLC10,312,167 8.87%Proxy statement (DEF 14A), table as of March 31, 2026
BlackRock10,068,614 8.66%Form 13F, quarter ended March 31, 2026
Vanguard Group8,971,347 7.72%Form 13F, quarter ended March 31, 2026
Two Sigma3,466,786 2.98%Form 13F, quarter ended March 31, 2026
AQR Capital3,001,521 2.58%Form 13F, quarter ended March 31, 2026
Renaissance Technologies2,974,683 2.56%Form 13F, quarter ended March 31, 2026
Geode Capital2,590,429 2.23%Form 13F, quarter ended March 31, 2026
State Street2,263,173 1.95%Form 13F, quarter ended March 31, 2026

Percentages above are of 116,272,513 shares outstanding, as reported by Fate Therapeutics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Fate Therapeutics, Inc.'s shareholder meeting held June 12, 2026, in the 2025-2026 proxy season, 140 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 905 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of the Company's named executive… — FOR was 97% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Fate Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 15, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Fate Therapeutics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Fate Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Fate Therapeutics (FATE) 2026 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/fate-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.